INSM Stock Insmed Incorporated

$141.33
1d-2.17%5d+16.65%1m+50.29%ytd-18.79%
At close · Nov 20, 4:00 PM ET
After hours $142.81 +1.05% · Nov 20, 7:09 PM ET
52w low $90.3942% of range$212.75 52w high
Price

Today’s call · INSM

All live ideas →

5 of 6 technical checks lean bullish

INSM is in an uptrend, momentum firm. $142.94 is the level overhead; $135.73 the first support below.

No open idea.From $141.33 the reward-to-risk to $142.94 against $135.73 is 0.3 — below the 3:1 bar.
What would create one:
  • A close above $142.94 on rising volume (breakout).
  • A pullback to $135.73 that holds (entry near support).
Alert me at a level

The brief

Price vs 50-day · abovePrice vs 200-day · above50d vs 200d avg · belowMACD · bullishRSI momentum · 735-day tape · +16.6%
levelPrice is 1.14% from resistance $142.94 — watch for a break or rejection.
momentumRSI 73.2 is overbought — the advance has been unusually fast.
volumeVolume is expanding vs its 20-day average.
signalINSM’s 50-day average is below the 200-day — long-term trend alignment is bearish.
All readings
TrendUptrend · above 50-day & 200-day
MomentumRSI 73.2 · overbought · MACD bullish
Trend strengthADX 35.2 · strong trend
Location+27.2% vs 50-day MA
52-week range-33% from high · +54% from low
VolatilityATR 7.18 · ~5.1%/day
RSI 14
73.2
MACD
7.42
ADX 14
35.2
ATR 14
7.18
SMA 50
$111.09
SMA 200
$122.56

Levels that matter

$142.94swing zone · 2×+1.1%
$150round+6.1%
$166.34swing zone · 3×+17.7%
$135.73swing zone · 2×−4.0%
$125round−11.6%
$122.56sma 200−13.3%
Next earnings: Oct 29Date, time & past reactions →

Compare with…

Analyst overview · Nov 20

Insmed Incorporated (INSM) stock analysis, November 20, 2026: bullish outlook with strong upside potential

Insmed Incorporated (INSM) closed at $141.06 on November 20, 2026, after a 2.4% pull‑back from a $144.46 peak the day before. The balance of evidence leans positive for the next two to six weeks, with a high conviction bullish stance supported by a daily trend that mirrors a weekly uptrend, a 40‑week price above its average, and a breakout math that exceeds a 3‑to‑1 reward‑to‑risk ratio. The stock remains well above its swing‑zone support at $135.73 and the 200‑day moving average at $122.56, giving the structure a solid floor while the upside target of $166.34 offers a 2.6‑to‑1 reward‑to‑risk profile.

Why it matters

The recent five‑day rally of 16.4% in INSM dwarfs the broader market, which fell 8.7% over the same period, and the healthcare sector ETF XLV, down 6.3%. This outperformance shows that the stock’s move was driven largely by its own dynamics rather than a sector‑wide rally. The daily price action has been riding the weekly uptrend, keeping the price above both the 10‑week and 40‑week averages, a sign that longer‑term buying pressure remains intact.

Analysts are overwhelmingly positive, with 22 forecasts averaging a price target of $194.18, a low of $158 and a high of $243. The current price sits 27.4% below the mean target, indicating that the consensus view leaves considerable upside room. The consensus rating of “strong buy” reinforces the notion that the market has not yet fully priced in the longer‑term earnings potential embedded in those targets.

The debate around INSM centers on two points. One side argues that the stock’s rapid 5‑day gain may be overstretched, pointing to a relative strength index of 72.9 that suggests the shares are approaching overbought territory. The other side counters that the RSI is merely reflecting the strong momentum and that the breakout math—requiring a close above $142.94 on volume 15.9% above the 20‑day average—still offers a favorable risk‑reward profile. Both arguments rely on the same numbers; the overbought concern is mitigated by the fact that the breakout level is still a few dollars away, and the volume surge confirms genuine buying interest.

Valuation remains a key piece of the puzzle. Even at the low end of the analyst range ($158), the stock would be trading at roughly 12% above the current price, while the high end ($243) implies a 72% upside. Those spreads are wide, but the consensus “strong buy” and the high conviction rating suggest that the market expects the company to deliver earnings growth that justifies those multiples.

What the evidence says

On the long‑term horizon, the thesis that INSM is in an uptrend remains intact. The price sits above its 40‑week average, the 200‑day moving average at $122.56 is well below the current level, and the 52‑week range shows the stock is 33.3% below its high of $211.41 but 53.5% above its low of $91.88. The structure holds above the swing‑zone support at $135.73, and the first crack below that zone would be a clear sign of weakening. In short, the long‑term picture is still bullish.

Looking ahead to the next two to six weeks, the balance of evidence is strongly positive. The assessment calls for a bullish stance with high conviction, based on three of four conviction points: the daily trend aligning with the weekly uptrend, a 50‑day outperformance of +39.6% versus the S&P 500, and a 50‑day outperformance of +26.3% versus XLV. The breakout math meets a 3‑to‑1 reward‑to‑risk ratio, with a target of $166.34 offering a 2.6‑to‑1 ratio and a farther target of $211.41 delivering 7.6‑to‑1. The strongest case against this reading would be a sudden drop below the swing‑zone support at $135.73, which would invalidate the current structure and force a reassessment. However, the price remains 5.3% above that level, and volume is still elevated, making such a move unlikely in the near term.

Levels that matter

The structure currently holds above $135.73, the swing‑zone support that also serves as the basis for the first crack‑below rule. A break beneath that level would signal the first sign of structural weakness. The trend would be considered ended if the price fell below the 200‑day moving average at $122.56, a level that would require a weekly close under that line to change the picture.

The breakout level sits at $142.94, the top of the swing‑zone resistance. A daily close above that price on volume at least 15.9% above the 20‑day average would confirm the upside breakout. The math from that point gives a primary target of $166.34, derived from the swing‑zone, with a reward‑to‑risk of 2.6. A secondary target of $211.41, the 52‑week high, provides a 7.6‑to‑1 reward‑to‑risk. Because the breakout math meets a 3‑to‑1 ratio, the risk‑reward profile is deemed attractive.

What would change the picture

A weekly close below the 200‑day moving average at $122.56 would alter the current outlook, indicating that the longer‑term uptrend has faltered. The non‑price factor that could trigger such a shift is a materially worse earnings result than expected on October 29, 2026, which could erode confidence in the growth narrative.

What to watch

  • Next earnings release on October 29, 2026 – focus on the earnings per share number and any guidance shift.
  • Sector developments that could affect healthcare biotechnology, such as FDA approvals or policy changes, which often move INSM ahead of its own news.
  • Valuation versus consensus: the stock trades about 27% below the mean analyst target of $194, leaving a sizable upside cushion if earnings meet expectations.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.